Cite
HARVARD Citation
Tripathy, D. et al. (n.d.). 166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC). Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tripathy, D. et al. (n.d.). 166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC). Annals of oncology. p. . [Online].